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Abstract: Background: Zika virus (ZIKV) infection has been associated with congenital microcephaly
and other neurodevelopmental abnormalities. There is little published research on the effect of
maternal ZIKV infection in a non-endemic European region. We aimed to describe the outcomes
of pregnant travelers diagnosed as ZIKV-infected in Spain, and their exposed children. Methods:
This prospective observational cohort study of nine referral hospitals enrolled pregnant women (PW)
who travelled to endemic areas during their pregnancy or the two previous months, or those whose
sexual partners visited endemic areas in the previous 6 months. Infants of ZIKV-infected mothers
were followed for about two years. Results: ZIKV infection was diagnosed in 163 PW; 112 (70%)
were asymptomatic and 24 (14.7%) were confirmed cases. Among 143 infants, 14 (9.8%) had adverse
outcomes during follow-up; three had a congenital Zika syndrome (CZS), and 11 other potential
Zika-related outcomes. The overall incidence of CZS was 2.1% (95%CI: 0.4–6.0%), but among infants
born to ZIKV-confirmed mothers, this increased to 15.8% (95%CI: 3.4–39.6%). Conclusions: A nearly
10% overall risk of neurologic and hearing adverse outcomes was found in ZIKV-exposed children
born to a ZIKV-infected traveler PW. Longer-term follow-up of these children is needed to assess
whether there are any later-onset manifestations.
Keywords: zika virus; microcephaly; congenital infection; adverse outcome; arboviruses
1. Introduction
Zika virus (ZIKV) infection constitutes one of the most challenging infectious epidemic outbreaks
worldwide to date. ZIKV is a uniquely challenging emerging zoonotic pathogen, with multiple routes
of transmission and teratogenic potential in fetuses [1]. The association of ZIKV infection in pregnancy
with congenital microcephaly and other neurodevelopment abnormalities in fetuses and infants was a
crucial factor underscoring the public health importance of this emergent virus [2–6]. In response to
the epidemic, the World Health Organization (WHO) recognized ZIKV as a public health emergency
of international concern (PHEIC) on 1 February 2016 [7].
Prenatal exposure to ZIKV is now a well-documented cause of severe microcephaly in infants [8].
In addition, evidence indicates that clinical presentation of congenital ZIKV syndrome (CZS) differs in
severity and prognosis depending on the head circumference (HC) at birth and the central nervous
system (CNS) damage [8]. Adverse clinical outcomes at birth or over the first year of life have been
described in different cohorts, affecting between 10% and 45% of the offspring exposed to ZIKV in
utero [9–14]. Most of these infants are expected to survive, and their estimated life span is expected
to be comparable to other children with microcephaly, epilepsy, and intellectual disability [15]. It is
important to note that consensus is lacking about the phenotype of CZS; however, fetal brain disruption
sequence [4,16,17] and neuropathology resembling congenital infections, such as toxoplasmosis or
cytomegalovirus (CMV), have been reported among infants with CZS [18]. Therefore, the long-term
impact of CZS may be severe for children and their families. The literature to date on CZS and children
exposed to ZIKV in utero is dominated by studies conducted in epidemic and endemic settings, where
individuals may be (re-)exposed to other flavivirus.
Spain started to report cases of Zika from 2016. Consequently, the government implemented
ZIKV surveillance of all pregnancies, as part of antenatal and maternal care, including women coming
from or having travelled to epidemic regions. Here, we report findings from the PedZikaRed study,
which was set up in Spain to take advantage of this unique opportunity to study ZIKV infection during
pregnancy and infant outcomes in a setting where ZIKV was not circulating.
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2. Results
2.1. Epidemiological and Clinical Characteristics of the Participants
A total of 179 pregnant women with ZIKV suspected infection were enrolled from January 2016
to February 2019. Participants were classified as a confirmed or probable ZIKV case following the
national guidelines [19]. A confirmed case was defined as a pregnant woman with (i) a positive reverse
transcriptase polymerase chain reaction (RT-PCR) test for ZIKV in serum and/or urine samples and/or
(ii) with a positive IgM against ZIKV, a negative IgM against dengue virus (DENV), and a ZIKV
neutralization titer ≥ 1/32. A ZIKV probable case was defined as a pregnant woman with an isolated
positive IgG test against ZIKV and a ZIKV neutralization titer ≥1/32 (Table 1).
Table 1. Classification of laboratory ZIKV diagnosis for pregnant women and their offspring.
RT-PCR IgG IgM PRNT
Confirmed
Positive
Negative or not done Positive Positive Positive
Probable
Negative or not done Positive Negative Positive
Negative or not done Positive Positive Negative
No evidence of Zika
Negative or not done Positive Negative Negative
Negative or not done Negative Negative Not done
ZIKV: Zika virus; RT-PCR: reverse transcriptase polymerase chain reaction; IgG: immunoglobulin G; IgM:
immunoglobulin M; PRNT: plaque reduction neutralization test for ZIKV.
For the analysis, 16 were excluded because of empty (n = 3) or duplicate records (n = 2), missing
date of diagnosis (n = 1), retrospective testing (n = 2), infection during a previous pregnancy (n = 1), or
not meeting eligibility criteria (i.e., no indication of infection) (n = 7). Thus, this paper presents the
data from 163 pregnant women and their infants included in the mother–child pair analyses (Figure 1).
The vast majority were Latin American immigrants (95.7%) who had travelled to visit family and
friends, whereas a small group was represented by European-born women (7/163; 4.3%) who travelled
to Latin America for tourism (Table 2).
2.2. Laboratory Confirmation of Maternal Infection
Screening for ZIKV occurred at a median (IQR) of 21 (14–30) gestational weeks. Median [IQR]
time of mother’s exposure at risk for ZIKV during pregnancy was 86 (31–162) days. Twenty-four
pregnant women (24/163; 14.7%) were classified as having confirmed ZIKV infection, of whom 14
tested positive for ZIKV RT-PCR, and ten tested positive for ZIKV-IgM and the ZIKV plaque reduction
neutralization test (PRNT). The rest of the participants were classified as probable maternal ZIKV
infection (139/163; 85.3%). From the whole group, 70% were asymptomatic, and only 21% of women
with probable ZIKV infection had symptoms compared to 83% of the 24 women with confirmed ZIKV
infection (p<0.0001). Rash was the most prevalent clinical finding (78%), followed by fever (67%)
and arthralgia (64%). Amniocentesis was performed in 30 women (19%), mostly in the group with
confirmed infections (16/24; 70%). Amniotic fluid ZIKV RT-PCR was positive in two of the cases
with CZS, the rest tested negative. Additionally, among 114 women screened for DENV infection,
109 tested positive for DENV-IgG, and eight also tested positive for DENV-IgM during pregnancy.
From the 72 women screened for chikungunya virus (CHKV), 27 tested positive for CHKV-IgG, and
three of these women had a positive CHKV-IgM result. One woman was found positive for human
immunodeficiency virus (HIV) as well as ZIKV, but had an HIV-uninfected infant who was healthy at
birth and throughout follow-up. No other active infections were detected among participants.
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Figure 1. Flowchart of the study population of the ot er–c il air ika Spanish cohort. *These
women were recruited from the total number of screened pregnant women in Spain due to their
relationship to where they were being cared for their pregnancy. TOP: termination of pregnancy.
2.3. Ultrasound and MRI Results during Pregnancies
Prenatal ultrasound was performed at least once in all but three women (160/163; 98.2%). Second
trimester ultrasound was normal in all but five cases (three with brain malformations associated with
CZS, one congenital heart disease associated wi h a 22q11 deletion syndrome, and one termination of
pregnancy (TOP) due to CZS). Neurologic magnetic resonance imaging (MRI) was perf rmed on 43
(26.4%) pregnant women; three showed f tal CNS abnormalitie (3/43; 7%): two of the CZS cas s, and
one infant with proportionate microcephaly b rn at 40 weeks of gestation th t was lost-to-follow-up
after first postnatal visit.
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Table 2. Maternal and pregnancy characteristics by maternal Zika virus infection status.
Confirmed Infection Probable Infection Total
n=24 n=139 n=163
n (%) or median [IQR]
Age at delivery (n = 157) 29 (24–35) 27 (23–32) 28 (23–32)
Total number of previous pregnancies (n = 162)
0 11 (46) 62 (45) 73 (45)
1 7 (29) 37 (27) 44 (27)
2 1 (4) 18 (13) 19 (12)
>=3 5 (21) 21 (15) 26 (16)
Total number of previous live births (n = 162)
0 13 (54) 78 (57) 91 (56)
1 7 (29) 37 (27) 44 (27)
2 3 (13) 12 (9) 15 (9)
>=3 1 (4) 11 (8) 12 (7)
Country of ZIKV exposure (n=163)
Dominican Republic 6 (25) 45 (32) 51 (31)
Honduras 4 (17) 34 (24) 38 (23)
Venezuela 0 (0) 17 (12) 17 (10)
Ecuador 3 (13) 11 (8) 14 (9)
Colombia 6 (25) 7 (5) 13 (8)
Bolivia 3 (13) 7 (5) 10 (6)
Other 2 (8) 18 (13) 20 (12)
Gestational age at screening (completed weeks)
(n = 162) 19 (11–25) 22 (15–31) 21 (14–30)
Clinical signs or symptoms (n = 161)
No 4 (17) 108 (78) 112 (70)
Yes* 20 (83) 29 (21) 49 (30)
Unknown 0 (0) 2 (1) 2 (1)
Fever (n = 49) 13 (68) 18 (67) 31 (67)
Rash (n = 49) 17 (85) 21 (72) 38 (78)
Arthralgia (n = 49) 12 (63) 16 (64) 28 (64)
Conjunctival hyperaemia (n = 49) 4 (22) 6 (24) 10 (23)
Guillain–Barre syndrome (n = 49) 1 (6) 1 (4) 2 (4)
Focal neurological signs (n = 49) 1 (6) 1 (4) 2 (4)
Other signs and symptoms (n = 49) 6 (33) 6 (23) 12 (27)
Screening sample <15 days after arrival in Spain
from endemic area (n = 141)
No 14 (58) 104 (89) 118 (84)
Yes 10 (42) 13 (11) 23 (16)
ZIKV IgM (n = 163)
Negative 7 (29) 139 (100) 146 (90)
Positive 17 (71) 0 (0) 17 (10)
ZIKV IgG (n = 163)
Positive 24 (100) 139 (100) 163 (100)
Amniocentesis performed (n = 159)
No 8 (33) 121 (90) 129 (81)
Yes 16 (67) 14 (10) 30 (19)
* p < 0.0001 for symptoms between confirmed and probable infections.
2.4. Maternal, Fetal, and Neonatal Outcomes
This section details the results based on 142 women who delivered 143 live-birth children (Table 3).
The median (IQR) duration of follow-up of the infants was 31 (IQR 13–50) weeks, with a maximum
follow-up time of 798 days. During the follow-up, 9.8% (14/143) (95%CI: 5.5–15.9%) infants had
adverse outcomes. There were three cases of CZS (two live-birth, one stillbirth), all born to mothers
with ZIKV-confirmed infection. The overall incidence of CZS was 2.1% (95%CI: 0.4–6.0%), and 15.8%
(3/19) (95%CI: 3.4–39.6%) among ZIKV-confirmed mothers. Eleven children had other potentially
Zika-related outcomes (OPZRO): five (3.5%) were diagnosed with mild hearing loss using a sequence
of automated auditory brainstem response (AABR) tests (one subsequently diagnosed with language
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impairment at 24 months of age) and six infants had abnormal neuroimaging results using either MRI
or ultrasound CNS scans (Table 4). Other congenital infections were ruled out for all cases, including
congenital CMV infection through viral load test in urine or saliva. None of the children with OPZRO
presented with any abnormal neurological development after birth. None of the three CZS cases
tested positive for ZIKV-IgM or ZIKV RT-PCR (blood, urine, CSF, and saliva) in the postnatal period.
ZIKV-IgG was initially positive for the two live-born CZS cases, but seroreversion was observed in
both after the first 12 months of life. Of note, the 22q11 deletion syndrome case detected was excluded
from the OPZRO group because there is no evidence to associate this pathology with ZIKV infection
among children.
Table 3. Birth and infant outcomes (livebirth and stillbirths only), by maternal Zika virus infection status.
Confirmed Infection Probable Infection Total
p-Valuen = 19 n = 124 n = 143
n (%) or Median [IQR]
Gestational age at delivery (completed weeks) (n = 143) 39 (37–40) 39 (39–40) 39 (38–40)
Preterm/term delivery (completed weeks) (n = 143) 0.305
<34 weeks (very preterm) 1 (5) 1 (1) 2 (1)
34–36 weeks (moderate preterm) 1 (5) 7 (6) 8 (6)
>=37 weeks (term) 17 (89) 116 (94) 133 (93)
Sex (n = 141) 0.475
Female 13 (68) 73 (60) 86 (61)
Male 6 (32) 49 (40) 55 (39)
Birth weight (g) (n = 140) 0.598
1500–2499 0 (0) 7 (6) 7 (5)
>=2500 17 (100) 116 (94) 133 (95)
Birth weight z-score (n = 138) 0.004
>=0 5 (29) 82 (68) 87 (63)
−2-<0 12 (71) 38 (31) 50 (36)
<−2 0 (0) 1 (1) 1 (1)
Head circumference at birth z-score (n = 129) 0.054
>=0 9 (60) 85 (75) 94 (73)
<0 & >=−2 4 (27) 28 (25) 32 (25)
<-2 2 (13) 1 (1) 3 (2)
Length at birth z-score (n = 127) 0.514
>=0 8 (57) 76 (67) 84 (66)
−2-<0 6 (43) 35 (31) 41 (32)
<−2 0 (0) 2 (2) 2 (2)
Type of delivery (n = 141) 1.000
Spontaneous 15 (79) 90 (74) 105 (74)
Assisted 1 (5) 6 (5) 7 (5)
Emergency Caesarean 0 (0) 5 (4) 5 (4)
Elective Caesarean 3 (16) 21 (17) 24 (17)
Child’s 1 minute Apgar score (n = 131) 0.014
=<3 0 (0) 1 (1) 1 (1)
4–6 2 (13) 0 (0) 2 (2)
=>7 14 (88) 114 (99) 128 (98)
Child’s 5 minute Apgar score (n = 131) 0.122
4–6 1 (6) 0 (0) 1 (1)
=>7 15 (94) 115 (100) 130 (99)
Congenital microcephaly (n = 131) 3 (16) 2 (2) 5 (4) 0.021
Cranial/facial disproportion (n = 131) 3 (16) 0 (0) 3 (2) 0.002
Arthrogryposis (n = 130) 1 (5) 0 (0) 1 (1) 0.146
Biparietal depression (n = 131) 2 (11) 1 (1) 3 (2) 0.009
Excess nuchal skin (n = 131) 2 (11) 0 (0) 2 (2) 0.054
Adverse outcomes related to Zika (n = 143) 0.001
Congenital Zika Syndrome 3 (16) 0 (0) 3 (2)
Other possible Zika-related outcomes 0 (0) 11 (9) 11 (8)
Asymptomatic 16 (84) 113 (91) 129 (90)
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Table 4. Abnormal/adverse outcomes in children born to ZIKV-infected mothers in the cohort.
Case
Mother’s
Country of
Exposure
Week of
Gestation at
Diagnosis
Maternal
Symptom
Method
Diagnosis for
Mother
Type of
Maternal
Infection
Week of
Gestation at
First US
Abnormal
Prenatal
Findings
Week of
Gestationat
Birth
Abnormal Physical Findings at Birth Abnormal Findings atFollow-up
CZS cases
1 Colombia 11 Yes
PCR-ZIKV (+)
in serum, urine
and amniotic
fluid
confirmed 12
Yes
(compatible
with CZS)
37
Yes (compatible with CZS): congenital
microcephaly (−5.1 z-score), craniofacial
disproportion, biparietal depression, excess
nuchal skin, and neurological abnormalities
CZS (congenital microcephaly,
collapsed skull, craniofacial
disproportion, arthrogryposis,
hyperexcitability, hyperreflexia,
abnormal mobility)
Abnormal cerebral MRI
findings (microcephaly with
cortical atrophy affecting
frontal lobes with pachygyria
pattern in both cerebral
hemispheres, delayed
myelination pattern,
microcalcifications in
parieto-occipital regions, global
thinning of the corpus
callosum, and moderate
supratentorial dysmorphic
ventriculomegaly)
2 Ecuador 13 No
PCR-ZIKV (+)
in serum, and
amniotic fluid
confirmed 13
Yes
(compatible
with CZS)
22
Stillbirth (necropsy pathological findings were
compatible with CZS):
microcephaly (168mm; reference for this
gestational age is 196 +/- 13mm), cortical atrophy,
ventriculomegaly,
bilateral polymicrogyria,
leptomeningeal glioneuronal heterotopia,
frequent calcifications in both hemispheres
CZS (microcephaly, partially
collapsed skull, cranio-facial
disproportion, and
arthrogryposis) PCR-ZIKV was
(+) in brain, CSF, placenta,
thyroid, trachea, heart,
quadriceps muscle, and bone
marrow
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Table 4. Cont.
Case
Mother’s
Country of
Exposure
Week of
Gestation at
Diagnosis
Maternal
Symptom
Method
Diagnosis for
Mother
Type of
Maternal
Infection
Week of
Gestation at
First US
Abnormal
Prenatal
Findings
Week of
Gestationat
Birth
Abnormal Physical Findings at Birth Abnormal Findings atFollow-up
CZS cases
3 Brazil 12 Yes
PCR-ZIKV (+)
in urine,
IgG-ZIKV (+),
and IgM-ZIKV
(+)
confirmed 29
Yes
(compatible
with CZS)
38
Yes (compatible with CZS): congenital
microcephaly (-3.5 z-score), craniofacial
disproportion, biparietal depression, excess
nuchal skin, and neurological abnormalities
CZS (congenital microcephaly,
collapsed skull, craniofacial
disproportion,
hyperexcitability, hyperreflexia,
abnormal mobility)
Abnormal cerebral MRI
findings (microcephaly with
cortical atrophy affecting
frontal lobes with pachygyria
pattern in both cerebral
hemispheres, abnormal
migration neuronal pattern,
calcifications in brain
parenchyma, basal ganglia and
periventricular regions,
dysgenesis of the corpus
callosum, cisterna magna
enlargement, and
ventriculomegaly)
Hearing loss findings
4 DominicanRepublic 14 Yes
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 14 No 40 No
Mild bilateral HL (abnormal
AABR test at 10-m-old)
LTFU after 10-m-old
5* DominicanRepublic 10 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 12 No 39 Disproportion moderate microcephaly (−2.1z-score below mean for age and sex)
Mild right HL (abnormal
AABR test at 5-m-old)
No microcephaly during
follow-up time
6 Honduras 29 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 34 No 40 No
Mild left HL (abnormal AABR
test at 15-m-old) Normal
cerebral MRI
Language impairment
7 Bolivia 30 Yes
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 31 No 39 No Mild left HL (abnormal AABRtest at 14-m-old)
8 Nicaragua 10 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 12 No 39 No Mild right HL (abnormalAABR test at 12-m-old)
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Table 4. Cont.
Case
Mother’s
Country of
Exposure
Week of
Gestation at
Diagnosis
Maternal
Symptom
Method
Diagnosis for
Mother
Type of
Maternal
Infection
Week of
Gestation at
First US
Abnormal
Prenatal
Findings
Week of
Gestationat
Birth
Abnormal Physical Findings at Birth Abnormal Findings atFollow-up
Abnormal postnatal cerebral MRI or head ultrasonographic findings in non CZS cases
9 Colombia 27 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 34 No 38 No
Postnatal U/S: Bilateral
lenticulostriate vasculopathy
Postnatal cerebral MRI: left
anterior arachnoid cyst
10 DominicanRepublic 15 Yes
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 21 No 35 No
Postnatal U/S: Hyper
echogenicity of the bilateral
periventricular white matter
LTFU at 12-m-old
11** DominicanRepublic 21 Yes
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 22
Yes
(intrauterine
growth
retardation)
34 No
Postnatal U/S: hemorrhage of
bilateral germinal matrix
Postnatal cerebral MRI:
Ventriculomegaly with
intraventricular hemorrhage,
ependymal and cisternae
siderosis, loss of volume of
bilateral cerebral white matter
and thinned corpus callosum
12 Ecuador 39 Yes
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 34 No 39 No
Postnatal U/S: lenticulostriate
vasculopathy in right basal
ganglia
13*** DominicanRepublic 18 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 18 No 40 No
Progressive microcephaly and
postnatal growth retardation
Postnatal cerebral MRI:
craniofacial disproportion
14**** Honduras 36 No
IgG-ZIKV (+)
plus
PRNT-ZIKV (+)
probable 38 No 40 Yes(complex seizures)
Postnatal U/S: asymmetry of
the germinal matrix
Postnatal cerebral MRI: acute
cortical-subcortical parietal and
occipital bilateral ischemic
lesions (left > right) due to
probable embolic cause
AABR: auditory automated brainstem response; CZS: congenital Zika syndrome; HL: hearing loss; IgG-ZIKV: immunoglobulin G against Zika virus; IgM-ZIKV: immunoglobulin M
against Zika virus; LTFU: lost-to-follow-up; MRI: magnetic resonance imaging; PCR-ZIKV: polymerase chain reaction for Zika virus; PRNT-ZIKV: plaque reduction neutralization test
for Zika virus; U/S: ultrasonography. * Case 5 had a moderate disproportionate microcephaly at birth but no microcephaly was observed during the follow-up time. ** Case 11 had
ventriculomegaly, loss of bilateral cerebral white matter volume, and dysgenesis of the corpus callosum alongside with intrauterine growth retardation. *** Case 13 had a HC within
normal parameters at birth but we observed a progressive microcephaly and postnatal growth retardation during the follow-up time of study. **** Case 14 had complex seizures just after
birth, the postnatal MRI showed multifocal arterial ischemic strokes.
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3. Discussion
To our knowledge, this is the first prospective cohort study of mothers and their children exposed
to ZIKV in an endemic area due to travel, who were diagnosed and followed-up in an European country.
The fact that the study was conducted in nine referral hospitals, most of them located in the two
biggest cities of Spain (Madrid and Barcelona), likely facilitated the recruitment of most ZIKV-infected
pregnant women in Spain during the study period. In addition, the participation of a diverse range of
health professionals demonstrates the need for a multidisciplinary approach to researching this newly
emerged congenital infection. In this manner, this study capitalized on the screening program in Spain
during the ZIKV epidemics in Latin America.
The results show that the great majority of our participants had been born in ZIKV endemic
countries (95.7%), mainly Latin American and Caribbean countries. It was found that 70% were
asymptomatic, and 14.7% classified as confirmed ZIKV. Interestingly, the RT-PCR assay remained
positive beyond the first fifteen days after arriving in Spain in 58% of women with confirmed ZIKV.
This result is consistent with previous observations and likely to be associated with a prolonged
viremia [20]. In addition, nearly 10% of the children born to mothers with confirmed or probable
maternal ZIKV infection had neurologic and hearing adverse outcomes possibly associated with ZIKV
exposure. This result supports published observations from a number of different countries such as
United States [13], French Territories in Americas [11], or French Guiana [10], but it is much lower
than the 42% observed in the Rio de Janeiro cohort [9]. Regarding audiological tests, 3.5% of children
had abnormal results, which is a smaller proportion compared to the from a Brazilian cohort [21], but
significant in relation to the results of a study in USA in which all ZIKV exposed infants of traveler
pregnant women passed the test [22]. Moreover, this percentage is 7-fold higher compared to rates of
hearing loss in the general child population of 5 per 1000 live births in Spain [23]. However, it has to
be noted that without longer-term follow-up we cannot infer the proportion of these children who
will definitively have audiological adverse outcomes, or rule out the possibility of delayed hearing
problems in children with normal results to date.
The prevalence of CZS was 2.1% overall, increasing to one in eight among children whose mothers
had confirmed infection, and congenital microcephaly was 40-fold higher than the estimated rate of 0.1
per 1000 live-births for this malformation in Spain [24]. Despite evidence that birth defects, including
OPZRO, can be detected regardless of trimester of infection, for the three CZS cases here maternal
infection occurred in the first trimester, as reported in other studies [9,25,26]. For one of the three CZS
cases, no maternal symptoms related to ZIKV infection were reported.
It is important to note that similar to other studies, this cohort faced important challenges with
respect to ZIKV laboratory diagnosis, including the short period for the detection of the ZIKV RNA [6]
and cross-reactivity in serological assays for ZIKV and DENV [25]. Similarly, this research faced
the lack of a gold standard serological test to determine the exact onset of ZIKV infection and the
ability to exclude other flavivirus infections such as DENV [9–14]. Our national referral laboratory
ISCIII in Madrid lacked the infrastructure to be able to perform any PRNT for other flaviviruses.
Other limitations included difficulties in following up all the screened pregnant women, precluding
comparison of pregnancy outcomes in ZIKV-infected women and in an uninfected control group. We
were also unable to confirm the maternal ZIKV diagnosis in most cases, giving a much lower sample
compared to other cohorts [9–11]. Finally, although we were able to assess frequency of OPZRO among
exposed children with respect to audiological and neurological adverse outcomes, we had insufficient
information regarding circumstances around elective or spontaneous abortions to be able to classify
these outcomes.
4. Materials and Methods
This multicenter prospective observational cohort study was conducted in nine referral hospitals.
Women who attended antenatal clinics located at Primary Health Centers for Reproductive and Sexual
Health were referred to these hospitals because they were classified as having been at risk of ZIKV
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exposure and therefore screened for ZIKV, as they came from or travelled to endemic areas during the
pregnancy or the 2 previous months or their sexual partners had visited endemic areas in the previous
6 months, and because they tested positive for ZIKV-IgG or ZIKV-IgM. It is important to highlight that
they were classified as exposed to ZIKV regardless the presence of symptoms. In addition, newborns
were enrolled in the study at birth and followed for a maximum of 2 years. Data collected from the
cohort of mother–child pairs was stored using REDCap Research Electronic Data Capture) [27]. The
study obtained approval from the ethical committees of all participating centers and the study protocol
followed the Spanish consensus document for the detection of ZIKV infection during pregnancy
published at the Ministry of Health website [19].
4.1. Enrolment Criteria
Pregnant women were eligible for recruitment when transferred to referral hospitals for the
reasons specified above. At recruitment, we collected demographic data, including maternal birth
date, birth country, ZIKV exposure country, presence of symptoms, and departure and return dates
from ZIKV endemic area. Likewise, blood and/or urine ZIKV samples were collected and analyzed via
RT-PCR commercial assay (RealStar®Zika Virus RT-PCR kit 1.0, Altona Diagnostics), ZIKV-IgG, and
ZIKV-IgM (IIFT Arboviral fever Mosaic IgG and IgM, Euroimmun, Germany from 2016 to December
2017; and ELISA Virus Zika IgG and IgM, Euroimmun, Germany, from December 2017 to the end of
study) (Table 1). If ZIKV RT-PCR was negative but ZIKV-IgG tested positive, specimens were sent
to the Instituto de Salud Carlos III (ISCIII, Madrid, Spain) for ZIKV-PRNT. However, ISCIII was not
able to perform specific PRNT for DENV; consequently, positive or equivocal ZIKV-PRNT titers were
not compared with DENV-PRNT results. Neutralization titer ≥1/32 was considered indicative of the
presence of ZIKV neutralizing antibodies. The date of ZIKV test was considered to be the date of
diagnosis for ZIKV infection.
4.2. Cohort Follow-Up and Endpoints
Women were evaluated by the high-risk obstetrics team when confirmed or probable ZIKV
infection was identified. Clinical evaluations, laboratory tests, and ultrasound (US) examinations were
performed according to the established standard of care. Serological tests (IgG/IgM) for DENV and
CHKV were used when possible to rule out co-infection with other arboviruses. Amniocentesis at
20–26 weeks of gestation with ZIKV RT-PCR testing of amniotic fluid was offered to all the mothers
with probable or confirmed ZIKV infection. If any abnormality was identified during prenatal US
examination, fetal MRI was performed. In addition, neonatal urine, serum, and saliva were sent
for ZIKV testing. If microcephaly or other neurodevelopment abnormalities were detected at birth,
diagnostic molecular tests for TORCH infections and a case history of participants were used to rule
out other possible causes of microcephaly.
The study considered the following endpoints for pregnancy outcomes; delivery of a live-born
infant with or without birth defects, miscarriage/spontaneous abortion, elective TOP before 20 weeks of
gestation, and stillbirth (intrauterine fetal death at or after gestational age of 20 weeks or intrapartum
death). The endpoints for children were the following clinical outcomes (by 31st March 2019); healthy
or asymptomatic; CZS; OPZRO.
All children born to women with confirmed or probable ZIKV infection in pregnancy were
followed-up to determine their clinical outcomes. According to standard of care, all of the participants
were offered follow-up for their children at 1, 4, 9, 12, 18, and 24 months of age. This usually included
neurological development assessment, ophthalmologic and hearing test, serological testing, cerebral
US, MRI, and AABR test. Demographic, anthropometric, clinical, and laboratory data were collected
for all the children born to ZIKV infected mothers. We defined an infant as a CZS case when she/he had
any of the severe neurologic birth defects included in the currently proposed definition of CZS [4,17].
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4.3. Statistical Analysis
Statistical analyses were conducted using Stata®15 (Stata Corp LLC, Texas, USA) and descriptive
statistics are presented for continuous and categorical data. To examine the association between
maternal and infant characteristics and confirmed or probable maternal infection status, we used χ2 or
Fisher exact tests according to sample size and reported p-values for each test.
5. Conclusions
In conclusion, among children born to pregnant women with confirmed or probable ZIKV infection
we found that nearly one in ten had neurologic and hearing adverse outcomes; where maternal ZIKV
infection was confirmed, this risk increased slightly to 15.8%. All three of the CZS cases occurred when
the mother was infected early in pregnancy. There is a need for continued and long-term follow-up of
children born to infected mothers to assess the incidence and define the characteristics of any potential
late-onset manifestations.
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